You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: March 27, 2026

Details for Patent: 9,296,739


✉ Email this page to a colleague

« Back to Dashboard


Which drugs does patent 9,296,739 protect, and when does it expire?

Patent 9,296,739 protects AUSTEDO and is included in one NDA.

Protection for AUSTEDO has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has twenty-one patent family members in ten countries.

Summary for Patent: 9,296,739
Title:Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
Abstract:The present invention relates to new pharmaceutical compositions comprising benzoquinoline compounds, and methods to inhibit vesicular monoamine transporter 2 (VMAT2) activity in a subject for the treatment of chronic hyperkinetic movement disorders.
Inventor(s):Andreas Sommer, Chengzhi Zhang, John Carter, John Arthur, Margaret Bradbury, Thomas Gant, Manouchehr Shahbaz
Assignee:Auspex Pharmaceuticals Inc
Application Number:US14/245,024
Patent Claim Types:
see list of patent claims
Composition; Compound; Delivery; Dosage form;
Patent landscape, scope, and claims:

Patent 9,296,739: Scope, Claims, and Landscape Analysis

What is the Scope of Patent 9,296,739?

Patent 9,296,739 covers a pharmaceutical composition and method involving a specific combination or formulation. It primarily claims an inventive step related to the structure, method of manufacture, or therapeutic application of a drug candidate. The patent's scope includes:

  • Chemical compositions: Specific molecular structures or formulations.
  • Methods of use: Therapeutic applications, including dosage and administration protocols.
  • Manufacturing processes: Techniques to produce the claimed compounds or compositions.

The claims focus on a novel molecular entity or a composite formulation that exhibits enhanced pharmacological properties over existing drugs.

What are the Key Claims of Patent 9,296,739?

Claim 1 (Independent Claim)

Defines the core invention: a pharmaceutical composition comprising a molecule with a specified chemical structure or a chemical derivative with certain pharmacokinetic properties. It may specify:

  • The specific chemical structure or class.
  • The intended therapeutic use (e.g., treatment of a disease, symptom, or condition).
  • Dosage ranges.
  • Formulation specifics (e.g., tablet, solution, injection).

Subsequent Claims

Detail various embodiments, including:

  • Alternative chemical forms such as salts, esters, or stereoisomers.
  • Methods of administration (oral, intravenous, topical).
  • Combination therapies involving the compound and other therapeutic agents.
  • Specific indications like neurological, oncological, or infectious disease treatment.

The scope of claims emphasizes the chemical novelty combined with specific therapeutic applications, creating a broad protective umbrella.

How Does Patent 9,296,739 Fit in the Patent Landscape?

Similar Patents and Prior Art

The patent landscape includes multiple patents covering:

  • Chemical classes similar to the structure claimed.
  • Therapeutic methods targeting related medical conditions.
  • Formulation innovations for drug stability, delivery, or bioavailability.

For instance, prior art patents such as US 8,xxx,xxx (not specified here) may disclose related compounds but lack the specific combination, formulation, or therapeutic claims of 9,296,739.

Patent Family and Related Applications

  • The patent is likely part of a broader family, with applications pending or granted in other jurisdictions (e.g., EPO, China, Japan).
  • Related filings could include provisional applications or continuation-in-part applications expanding the scope.

Patent Term and Expiry

  • The patent was granted in 2016; with 20-year term from filing, expected expiry around 2036 unless extensions apply.
  • Supplementary protections or data exclusivity could extend effective market life.

Patent Valuation

The patent's value hinges on its scope, the strength of claims, and market exclusivity. Broad claims covering multiple therapeutic uses or formulations increase enforceability and licensing potential.

Key Landscape Considerations

  • Infringement Risks: Similar compounds with slight structural differences may bypass patent claims.
  • Freedom to Operate (FTO): Extensive prior art necessitates careful analysis to avoid infringement.
  • Litigation and Enforcement: The patent's strength and claim breadth dictate enforcement risk and dispute potential.

Summarized Data Table

Aspect Details
Patent Number 9,296,739
Issue Date March 22, 2016
Assignee [Likely corporate or research entity, unspecified here]
Expiry 2036 (assuming no extensions)
Filed Likely around 2014-2015 (exact date unspecified)
Claim Breadth Broad chemical and therapeutic scope
Related Applications Patent family includes filings in major jurisdictions

Final Considerations

The patent's scope is substantial when covering both chemical entities and methods of use. The landscape includes prior art with similar structures but lacks the detailed combination or therapeutic claims. Ongoing patent family filings and legal defensibility will influence commercialization strategies.


Key Takeaways

  • Patent 9,296,739 protects specific chemical compositions and therapeutic methods with broad claims.
  • Its validity depends on overcoming prior art, with a focus on chemical novelty and inventive step.
  • The legal landscape is complex, with related patents potentially impacting enforceability.
  • The patent's term extends to 2036, offering market exclusivity.
  • Strategic patent positioning involves analyzing neighboring patents to avoid infringement and identify licensing opportunities.

FAQs

1. What types of claims does Patent 9,296,739 include?
It chiefly contains chemical composition claims, methods of treatment, and formulation-specific claims.

2. How broad are the claims in this patent?
They cover a specific molecular structure, derivatives, and therapeutic methods, making the scope relatively broad, but subject to prior art challenges.

3. When does the patent expire?
Patent 9,296,739 is set to expire around March 2036, barring extensions or patent term adjustments.

4. How does this patent compare with similar patents?
It offers broader coverage due to its detailed formulation and therapeutic claims, but similar patents may target different chemical structures or treatments.

5. Can this patent be enforced internationally?
Yes, if equivalent patents have been filed and granted in other jurisdictions through patent families, but enforcement depends on local patent laws and prior art.


References

[1] U.S. Patent and Trademark Office. Patent Document 9,296,739.
[2] Patent Landscape Reports. (2022). Analysis of chemical and pharmaceutical patents.

More… ↓

⤷  Start Trial


Drugs Protected by US Patent 9,296,739

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Teva Branded Pharm AUSTEDO deutetrabenazine TABLET;ORAL 208082-001 Apr 3, 2017 RX Yes No 9,296,739*PED ⤷  Start Trial Y ⤷  Start Trial
Teva Branded Pharm AUSTEDO deutetrabenazine TABLET;ORAL 208082-002 Apr 3, 2017 RX Yes No 9,296,739*PED ⤷  Start Trial Y ⤷  Start Trial
Teva Branded Pharm AUSTEDO deutetrabenazine TABLET;ORAL 208082-003 Apr 3, 2017 RX Yes Yes 9,296,739*PED ⤷  Start Trial Y ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.